Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Nxera Pharma UK Limited has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed across 3 examiners and 3 art units, indicating that the current prosecution workload spans separate examination assignments rather than being concentrated in one technical group.
JEAN-LOUIS, SAMIRA JM is the busiest examiner, with 1 pending matter. Counsel should therefore assess each examiner and art-unit position separately, while giving particular attention to the issues presented in that examiner’s case.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JEAN-LOUIS, SAMIRA JM | 1 | 60.9% | +45.4% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
| COFFA, SERGIO | 1 | 61.1% | +32.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18867575 | CRYSTALLINE FORMS AND SALTS OF A MUSCARINIC RECEPTOR AGONIST | JEAN-LOUIS, SAMIRA JM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18031416 | LINEAR APELIN RECEPTOR AGONISTS | COFFA, SERGIO | 20d |
| 18867575 | CRYSTALLINE FORMS AND SALTS OF A MUSCARINIC RECEPTOR AGONIST | JEAN-LOUIS, SAMIRA JM | — |
| 18826098 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | WHITE, DAWANNA SHAR-DAY | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1627 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18867575 | CRYSTALLINE FORMS AND SALTS OF A MUSCARINIC RECEPTOR AGONIST | JEAN-LOUIS, SAMIRA JM | 1642 | §102§112 | Non-Final OA | — | Pending | Nov 20, 2024 |
| 18826098 | PYRAZOLE DERIVATIVES AS H4 ANTAGONIST COMPOUNDS | WHITE, DAWANNA SHAR-DAY | 1627 | §103§112DP | Non-Final OA | — | Pending | Sep 05, 2024 |
| 18031416 | LINEAR APELIN RECEPTOR AGONISTS | COFFA, SERGIO | 1658 | §112 | Non-Final OA | 20d | Pending | Apr 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNxera Pharma UK Limited has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Samira Jm Jean-Louis has the most, with 1 of Nxera Pharma UK Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
